Concepedia

Ikechukwu Adigweme

IA

Statistics

Publications

6

Citations

247

H-Index

6

Active since

2016

Affiliations

MRC Unit the Gambia(Current)

Serum Institute of India (India)

Program for Appropriate Technology in Health

University College London

Centers for Disease Control and Prevention

Ikechukwu Adigweme is an author at MRC Unit the Gambia specializing in vaccination, pediatric vaccination, and veterinary medicine.

Publications per year

2016–2024

6

Publications

6

A measles and rubella vaccine microneedle patch in The Gambia: a phase 1/2, double-blind, double-dummy, randomised, active-controlled, age de-escalation trial

Ikechukwu Adigweme, Mohammed Nakodi Yisa, Michael Ooko et al. · The Lancet · 2024 · 81 citations · Full text

, , +17

Safety and immunogenicity of inactivated poliovirus vaccine when given with measles–rubella combined vaccine and yellow fever vaccine and when given via different administration routes: a phase 4, randomised, non-inferiority trial in The Gambia

Ed Clarke, Yauba Saidu, Jane U. Adetifa et al. · The Lancet Global Health · 2016 · 55 citations · Full text

, , +17

Immunogenicity and safety of a novel ten-valent pneumococcal conjugate vaccine in healthy infants in The Gambia: a phase 3, randomised, double-blind, non-inferiority trial

Ed Clarke, Adedapo Olufemi Bashorun, Ikechukwu Adigweme et al. · The Lancet Infectious Diseases · 2021 · 41 citations · Full text

, , +17

Safety and immunogenicity of a novel 10-valent pneumococcal conjugate vaccine candidate in adults, toddlers, and infants in The Gambia—Results of a phase 1/2 randomized, double-blinded, controlled trial

Ed Clarke, Adedapo Olufemi Bashorun, Michael Okoye et al. · Vaccine · 2019 · 32 citations · Full text

, , +17

Study protocol for a phase 1/2, single-centre, double-blind, double-dummy, randomized, active-controlled, age de-escalation trial to assess the safety, tolerability and immunogenicity of a measles and rubella vaccine delivered by a microneedle patch in healthy adults (18 to 40 years), measles and rubella vaccine-primed toddlers (15 to 18 months) and measles and rubella vaccine-naïve infants (9 to 10 months) in The Gambia [Measles and Rubella Vaccine Microneedle Patch Phase 1/2 Age De-escalation Trial]

Ikechukwu Adigweme, Edem Akpalu, Mohammed Nakodi Yisa et al. · Trials · 2022 · 25 citations · Full text

, , +17

1–5 of 6